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Abstract
BACKGROUND: Iodine can reduce breast tumor progression by mediates an antiproliferative effect. 
AIM: This study aimed to investigate the effect of iodine (I2), Lugol (I3K), and the combination of both on cell 
proliferation of three different types of breast cancer cell lines.
METHODS: The samples were MCF7, SKBR3, and MDA-MB 213 cell lines. Cell proliferation rate was measured 
using colorimetric and clonogenic assays.
RESULTS: The cell proliferation rate of MDA-MB 231 cells was reduced significantly by treatment I2, I3K, 
and combination of both with p = 0.046, p = 0.00, and p = 0.00, respectively. In MCF7 cells, I2 reduced the cell 
proliferation of 54–94% and I3K reduced the proliferation of 74–94%. The effectiveness of I3K treatments in slowing 
cell proliferation rate was dose-dependent. In SKBR3 cells, I2 reduced proliferation cell up to 85% and I3K 4%-94% 
depending on the dose. Clonogenic assay results showed a discontinue of the cell proliferation by all doses of I2 and 
I3K (10 µM and 20 µM). 
CONCLUSION: Breast cancer cell lines, representing subtypes of luminal A, HER2+, and triple-negative, show an 
excellent response to iodine treatments and I3K response shows in a dose-dependent manner. Further studies are 
needed to investigate the effective in vivo doses.
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Introduction
Iodine plays a pivotal role in maintaining the 
mammary gland’s normal healthy integrity and its 
deficiency transmutes a healthy structure and function of 
rat mammary gland [1], [2]. Some of the studies reported 
that iodine mediates apoptosis and has an effect on 
antineoplastic process [3], [4], [5]. Iodine consumption 
of 3–6 mg/day has reduced breast hyperplasia, per 
lobular/ductal fibrosis, and slowing down breast cancer 
progression [6], [7]. Iodine mediates antiproliferative 
effects directly or indirectly. Oxidized iodine eliminates 
the mitochondrial membrane potential (MMP) to mediate 
apoptosis directly or by forming iodolipids and activation 
of gamma type peroxisome proliferator-activated 
receptors γ (PPARγ) that trigger apoptosis [2], [5], [8], [9].
Cancer disease is the second leading cause 
of death globally; it caused more than ten million death 
annually [10], [11], [12]. The incidence rate of breast 
cancer in the United States (US) increased slightly by 
0.3% per year, but the mortality rate declined by around 
40% from 1989 to 2017 [13]. The Asian region has the 
lowest breast cancer mortality in the world [5]. Globocan 
report 2018 said that new breast cancer cases in the US 
are higher than in Japan (7.5%:11%) [12]. Seaweed is 
a common dietary component in Japanese and it is a 
rich source of iodine. Japanese iodine consumption is 
25 times higher than in Western countries. It has been 
associated with the low incidence of breast cancer in 
Japanese people compared to Western [2]. However, 
breast cancer number in Japan continues to increase that 
may be exposed to the western diet and lifestyle [14].
Breast cancer was classified based on 
histopathology findings. Advanced techniques such 
as immunohistochemistry define the molecular 
subtypes based on the expression of estrogen 
receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor-2 positive (ERBB2/
HER2+) [15], [16], [17]. Identification of the molecular 
subtypes of breast cancer is essential for a personalized 
treatment plan and predict prognosis. Some breast cancer 
subtypes are resistant to some therapies [15], [17], [18]. 
Limitation of the benefit of available therapy challenges 
an emerge of new alternative therapy for breast cancer.
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The total amount of iodine in the human body is 
around 30–50 mg. Less than 30% presents in the thyroid 
gland. Around 60–80% is concentrated in extrathyroidal 
tissues. These include salivary glands, gastric mucosa, 
lactating mammary gland, the choroid plexus, and et 
cetera [1], [19]. Non-lactating breast tissue is known to 
be NIS and peroxidase poor and does not provide for 
organification [4].
I2 is taken up by a non-lactating mammary gland 
without the involvement of NIS and peroxidase activity, 
and it is a highly reactive species [2], [4], [20]. I2 mediates 
antiproliferative effect with direct or indirect action. In vitro 
studies showed that I2 exposure induced the mitochondria 
to release apoptosis factors that cause nuclear 
fragmentation directly [4], [21]. On the other hand, breast 
tumor tissues contain arachidonic acid (AA) more than the 
normal ones. Iodination of AA formed 6-iodolactone (6-IL), 
which is an essential membrane lipid. PPARγ could be the 
mediator of the 6-IL apoptotic effect [1], [3], [5].
This study investigates the proliferation rates of 
I2, I3K, or a combination of both in various concentrations 
treatments of three types of breast cancer cell lines. It 
will obtain the potential extrathyroidal benefits of iodine 
and alternative breast cancer therapy.
Materials and Methods
Cell lines and culturing
This study uses three types of breast cancer 
cell lines MCF7 (estrogen and progesterone positive 
receptors/ER+ and PR+) and SKBR3 (human epidermal 
growth factor receptor 2+/HER2+) and MDA-MB 231 
(triple-negative) [18]. SKBR3 was purchased from the 
American Type Culture Collection, MCF7, and MDA-MB 
231 cell lines were gifted from the Faculty of Medicine, 
Universitas Padjadjaran, Bandung-Indonesia. MCF7 
and MDA-MB 231 cells were cultured in RPMI 1640 
medium (Invitrogen). SKBR3 was cultured in McCoy’s 
5A medium (Invitrogen). Mediums were added with 
10% fetal bovine serum (Invitrogen), 1% penicillin, 1% 
streptomycin, and 1% amphotericin B. The cells were 
incubated at 37°C and supplied with 5% carbon dioxide 
(CO2) until 90% confluence was reached.
Proliferation rates
The cells’ proliferation rate was measured 
using a colorimetric assay and clonogenic test.
Colorimetric assay
Methyl thiazolyldiphenyl-tetrazolium bromide 
for iodine and Lugol and radioiodine treatments was 
used to measured cell proliferation rate. The cultured 
cells were washed with phosphate-buffered saline 
(PBS) twice, then seeded in a 96-well plate at a density 
of ×2 104/well and incubated for 24 h then treated with 
1 µM, 10 µM, 20 µM of I2, I3K, and a combination of I2 
and I3K. The treatments were done for 24, 48, and 72 h, 
and it carried out in triplicate. The control cells were 
treated with medium only. MTT (5 mg/ml in PBS) was 
added to the wells, and the plate was incubated for 4 h at 
37°C. The medium was removed, and 100 ml dimethyl 
sulfoxide was added to the wells, and the absorbance 
was measured at 550 nm using a colorimetric.
The proliferation rate was calculated by the 
equation:
( ) −= ×
−
O D  test O D  b lankC e ll  p ro life ra tion  %  100
O D  con tro l O D  b lank
Clonogenic assay
Cells were grown in six-well culture plates 100 
cells/well, for a day. The next day, the cells were incubated 
for 72 h in 5% CO2 at 37°C with 1 µM, 10 µM, and 20 µM 
of I2, I3K, and a combination of both. The reaction was 
terminated by removing the iodine-containing medium, 
and the cells were washed twice with cold PBS. The cells 
were then grown for 12 days in the mediums. They were 
supplemented with 10% fetal bovine serum (Invitrogen), 
1% penicillin, 1% streptomycin, and 1% amphotericin 
B. The cells were then washed with PBS, fixed with 
methanol/water (1:1), and then stained with crystal 
violet. Macroscopic colonies were counted. These 
experiments were performed twice. The proliferation rate 
was calculated as the number of cell colonies in plates 
treated with I2, I3K, and a combination of both compared 
with those untreated cells.
Statistical analysis
All experiments were performed in triplicate. 
Results are presented as means ± standard deviation. 
Statistical significance comparing experimental 
values used non-parametric tests (Kruskal–Wallis and 
Mann–Whitney test). One-way ANOVA and post-hoc-
Bonferroni for the parametric test were performed.
Results
MDA-MB 231 cell lines
The averages of the cell proliferation after 
treatments of I2, I3K, and combination of I2–I3K (1 µM) were 
98 ± 5%, 88 ± 33%, and 110 ± 3%, respectively, 95 ± 6%, 
80 ± 6%, and 79 ± 7% respectively, and 55 ± 8%, 53 ± 8%, 
and 47 ± 7%, respectively, as shown in Table 1. The cell 
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proliferation rate of MDA-MB 231 cells was reduced 
significantly by treatment I2, I3K, and combination of both 
with p = 0.040, p = 0.001, and p = 0.001, respectively, 
as shown in Figure 1. Treatment doses of 10 µM and 
20 µM reduced cell proliferation significantly compared to 
the dose of 1 µM with p = 0.001 and p = 0.001. 
The antiproliferation rate of I2, I3K, and 
combination of both for 24, 48, and 72 h treatment, 
not differ significantly. The treatment combination did 
not show different results compared to I2, I3K alone 
p = 0.177, p = 0.066, and p = 0.329.
MCF7 cell lines
The averages of the cell proliferation after 
treatments of I2, I3K, and combination of I2, and I3K 
(1 mM) for 24 h were 60 ± 7%, 140 ± 56%, and 273 
± 106%, respectively, for 48 h were 66 ± 31%, 114 ± 
98%, and 103 ± 13%, respectively, and for 72 h were 
27 ± 17%, 162 ± 22%, and 105 ± 11%, respectively, as 
showed in Table 2. Iodine treatment showed a reduced 
cell proliferation rate of MCF7, and the effect did not 
make a significant difference between those doses, 
as shown in Figure 2. Treatment of Lugol 10 µM and 
20 µM reduced cell proliferation significantly compared 
to Lugol 1 µM, with p = 0.001 and p = 0.001, respectively. 
The combination of I2 and I3K 10 µM and 20 µM reduced 
cell proliferation significantly compare to 1 µM dose, 
with p = 0.001 and p = 0.010, respectively. There is no 
significantly different effect on cell proliferation between 
combination treatments of I2 and I3K of 10 µM with 20 µM.
SKBR3 cell lines
The averages of the cell proliferation after 
treatments of I2, I3K, and combination of I2 and I3K 
(1 µM) for 24 h were 29 ± 10%, 96 ± 20%, and 93 ± 
23%, respectively, for 48 h were 25 ± 21%, 141 ± 75%, 
and 111 ± 70%, respectively, and for 72 h were 27 ± 
17%, 335 ± 216%, 242 ± 80%, respectively, as shown 
in Table 3. Iodine reduced proliferation cell up to 85%. 
The antiproliferative effect did not differ between I2 
treatment doses, as shown in Figure 3. However, the 
Table 2: MCF7 cells line proliferation rate after 1, 10, and 20 µM 
of I2, I3K and a I2-I3K combination
MCF7 (%) Cell proliferation Cell proliferation Cell proliferation p
Means ± SD (%)
24 h
Means ± SD (%)
48 h
Means ± SD (%)
72 h
I2
1 60 ± 7 66 ± 31 27 ± 17 0.144
10 52 ± 6 16 ± 11 17± 9 0.010
20 28 ± 21 25 ± 19 6 ± 4 0.280
p 0.113 0.099 0.177
I3K
1 140 ± 56 114 ± 98 162 ± 22 0.689
10 120 ± 34 30 ± 16 26 ± 10 0.001
20 36 ± 24 6 ± 6 12 ± 10 0.154
p 0.055 0.042 0.001
I2+I3K
1 273 ± 106 103 ± 13 105 ± 11 0.021
10 115 ± 28 33 ± 9 21 ± 9 0.065
20 32 ± 22 14 ± 6 14 ± 11 0.275
p 0.010 0.000 0.000
Table 1: MDA-MB231 cells proliferation rate after 1, 10, and 
20 µM of I2, I3K and a I2-I3K combination
MDA-MB 231 Cell proliferation Cell proliferation Cell proliferation p
(%) Means ± SD (%) 
24 h
Means ± SD (%) 
48 h
Means ± SD (%)
72 h
I2
1 98 ± 5 95 ± 6 55 ± 8 0.001
10 20 ± 20 11 ± 9 8 ± 8 0.590
20 16 ± 23 12 ± 10 10 ± 10 0.940
p 0.061 0.055 0.063
I3K
1 88 ± 33 80 ± 6 53 ± 8 0.170
10 32 ± 22 18 ± 15 7 ± 7 0.360
20 22 ± 21 16 ± 14 9 ± 7 0.730
p 0.079 0.061 0.055
I2 + I3K
1 110 ± 3 79 ± 7 47 ± 7 0.490
10 16 ± 23 13 ± 10 15 ± 13 0.449
20 17 ± 25 11 ± 18 13 ± 16 0.709
p 0.066 0.055 0.066
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Figure 1: MDA-MD 231 cell proliferation rate of various treatments of iodine, Lugol, and combination of both for 24, 48, and 72 h. The 
proliferation rates reduced significantly with treatments 10 µM and 20µM compared to 1 µM (p = 0.001, p = 0.001, and p = 0.001), respectively.
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treatment effect of I3K and a combination of I2 and I3K 
depends on the dose, with p = 0.001 and p = 0.001 for 
24 h, respectively, and p = 0.006 and p = 0.008 for 72 h, 
respectively. The combination of I2 and I3K (1 µM) had 
no different results with I3K (1 µM) alone, with p = 0.623.
Clonogenic result
Iodine treatment in varying doses discontinues 
the cell proliferation, as shown in Table 4 and Figure 4. 
Even though I3K 1 µM dose did not affect in the slowing 
of cell proliferation, but 10 µM and 20 µM doses 
suppressed cell proliferation.
Discussion
In thyroid cell and lactating mammary gland, 
iodide transport is facilitated by NIS [6], [22]. Iodide 
excess induces apoptosis in thyrocytes, and the 
effect depends on thyroid peroxidase [3]. On the 
other hand, non-lactating mammary gland has a low 
level of peroxidase. The condition does not provide 
the environment for iodide organification. However, I2 
can be utilized without sodium iodide symporter and 
peroxidase [19], [23]. I2 treatment in benign breast cancer 
has been found to reduce tumor size and symptoms, 
but not I- treatment [6]. Iodide is preferentially taken 
up and retained in the thyroid and lactating mammary 
glands, but the pituitary, ovary, and non-lactating breast 
glands, I2 are taken up more readily than I
- [6], [22].
Iodine in breast tissue was explained by 
in vitro studies that I2 is taken up through diffusion, 
then incorporated into iodolipids and nuclear 
components, then exert antiproliferative and 
apoptotic properties [3], [19], [24]. Previous studies 
have reported that the antiproliferative effects of I2 
are through MMP destruction that directly results 
in apoptosis. MMP is needed for mitochondrial 
functions such as ATP production, metabolite transport 
regulation, and protein import. The mitochondrial 
intermembrane space contains several proteins that 
induce apoptosis through cytochrome c induction 
or activation of a caspase-independent apoptotic 
death program [3], [8], [9], [25]. Furthermore, iodine’s 
antiproliferative effect can occur through iodolipid 
formation, 6-IL, or alpha-iodohexane canal, and the 
activation of PPARγ interaction through increased BAX, 
caspases 3, 7, p53, and p21 [1], [3], [21], [25].
Table 4: The clonogenic assay results in MDA-MB 231, SKBR3, 
and MCF7 cell lines after 1 µM, 10 µM, and 20 µM of I2, I3K 
treatments
Doses (%) MDA-MB 231 SKBR3 MCF7
I2
1 0 0 0
10 0 0 0
20 0 0 0
I3K
1 230 ± 25 (62.8%) 208 ± 34 (39.8%) 284 ± 51 (71%)
10 0 0 0
20 0 0 0
Control 366 ± 8.5 523 ± 28.3 400 ± 28.3
Table 3: SKBR3 cells proliferation rate after 1, 10, and 20 µM of 
I2, I3K and combination of I2-I3K treatments
SKBR3 (%) Cell proliferation
Means ± SD (%)
24 h
Cell proliferation
Means ± SD (%)
48 h
Cell proliferation
Means ± SD (%)
72 h
p
I2
1 29 ± 10 25 ± 21 27 ± 17 0.220
10 15 ± 3 17 ± 15 15 ± 10 0.988
20 16 ± 16 19 ± 14 24 ± 15 0.226
p 0.236 0.381 0.413
I3K
1 96 ± 20 141 ± 75 335 ± 216 0.148
10 16 ± 6 15 ± 10 11 ± 10 0.560
20 6 ± 6 24 ± 18 10 ± 6 0.582
p 0.001 0.069 0.006
I2 + I3K
1 93 ± 23 111 ± 70 242 ± 80 0.23
10 11 ± 8 17 ± 12 16 ± 14 0.94
20 14 ± 12 21 ± 10 25 ± 11 0.83
p 0.001 0.215 0.008
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Figure 2: MCF7 cell proliferation rate of various iodine, Lugol treatments, and a combination of both for 24, 48, and 72 h. Iodine treatment doses 
reduced cell proliferation did not depend on the dose. Lugol and a combination of I2 and I3K (10 µM) showed an antiproliferative effect after 48 
and 72 h of treatments p = 0.010 and p = 0.001, respectively
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Recently, a study has reported that I2 treatment 
did not have an antiproliferative effect in MDA-MB 231 
cells [4]. This study found that the proliferation MDA-MB 
231 cell discontinued by I2 treatment, as shown in 
Figures 1 and 4. The low dose of I3K (1 µM) showed 
a limitation of the MDA-MB 231 cells’ antiproliferation 
effect. However, 10 µM and 20 µM of I3K and a 
combination of I2 and I3K reduced cell proliferation 
significantly with p < 0.05 (Table 1). A combination of 
treatments did not show an increasing effect when 
it is compared with I2 and I3K alone. I3K reduces cell 
proliferation effect in this study, in line with a study by 
Rösner et al. [6]. The clonogenic result showed that I2 
doses inhibited cell proliferation and I3K (10 µM and 
20 µM), as shown in Figure 4. However, the mechanism 
of iodine induces apoptosis in MDA-MB 231 has yet to 
be elucidated.
Meanwhile, I2 inhibited the proliferation 
of MCF7 cells was not a dose-dependent manner 
(Table 2). The treatment reduced cell proliferation 
by up to 94%. This finding has a similar result with 
previous studies [3], [5], [26]. Furthermore, a study 
Figure 4: Clonogenic assay results, as shown on MCF7 (top), MDA-MB231 (middle), and SKBR3 (below). From left to right are results of the 
clonogenic assay of 1, 10, and 20µM of I2 and I3K and control cells. I2 suppresses cell proliferation in all doses, and the same effect showed in 
10 µM and 20 µM of I3K
0
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Figure 3: SKBR3 cell proliferation rate of the various treatment doses of iodine, Lugol, and a I2-I3K combination for 24, 48, and 72 h. Iodine 
reduced the cell proliferation did not depend on the dose. Lugol and combination iodine and Lugol showed reduced cell proliferation with 10 µM 
and 20 µM with p = 0.001 and p = 0.001, respectively
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reported that I2 treatment was found to inhibit MCF7 cell 
growth, that even more effective than in MDA-MB 231 
cells [1], [21]. In this study, I2 treatments show similar 
effective in MCF7, MDA-MB 231, and SKBR3 cells from 
the clonogenic result. I2 treatment increases the apoptotic 
rate and PPARγ expression, leading to a decrease 
in proliferation and dissipating the estrogen receptor 
alpha’s translocation to the nucleus [3]. As MCF7 and 
MDA-MB 231 cells express PPARγ receptors, it can 
be hypothesized that the antiproliferation mechanism 
of I2 in both cell lines is likely to be through iodine-
PPARγ receptor interactions [21], [27]. Further studies 
are needed to explore it. Furthermore, I3K treatments 
showed an antiproliferation effect on MCF7 exerts a 
dose-dependent manner. Nevertheless, a combination 
of I2 and I3K inhibited cell proliferation did not increase 
significantly compared with I3K treatment alone, as 
shown in Table 2. The clonogenic result showed that I3K 
(10 µM and 20 µM) effectively to stop cell proliferation 
(Figure 4).
SKBR3 cells do express NIS and showed that 
they could take radioiodine [28], [29]. In this study, I2 
and I3K showed an antiproliferative effect, as shown in 
Table 3. The iodine effect did not change by a different 
dose. However, antiproliferative effect of I3K and the 
combination of I2 and I3K tend to increase with higher 
doses (Table 3). The clonogenic result showed I3K 
(10 µM and 20 µM) effectively to discontinued SKBR3 
cell proliferation (Table 4). Further investigations are 
needed to elaborate on the mechanism of the apoptotic 
process of iodine exposure in breast cancer.
Conclusion
Iodine treatment was sufficient to discontinue 
cell proliferation of MCF7, MDA-MB231, and SKBR3 
cells. The antiproliferative effect of I3K shows in a 
dose-dependent manner. Breast cancer cell lines, 
representing subtypes of luminal A, HER2+, and 
triple-negative, show an excellent response to iodine 
treatments. Further studies are needed to investigate 
the effective dose of iodine to breast cancer subtypes 
in vivo and the effect toward the normal cell. This 
finding opens the opportunity of using iodine for breast 
cancer prevention as well as an alternative therapy.
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